Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Schwab Fundamental US Large Company Index ETF
FNDX
|
+$8.54B |
| 2 |
Vanguard Mortgage-Backed Securities ETF
VMBS
|
+$6.22B |
| 3 |
Schwab US Large- Cap ETF
SCHX
|
+$6.12B |
| 4 |
Schwab Fundamental US Small Company Index ETF
FNDA
|
+$5.39B |
| 5 |
Schwab 5-10 Year Corporate Bond ETF
SCHI
|
+$5.01B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Texas Instruments
TXN
|
+$367M |
| 2 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$335M |
| 3 |
Diageo
DEO
|
+$297M |
| 4 |
Medtronic
MDT
|
+$259M |
| 5 |
GE Aerospace
GE
|
+$222M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.36% |
| 2 | Financials | 10.66% |
| 3 | Healthcare | 9.68% |
| 4 | Consumer Discretionary | 8.35% |
| 5 | Industrials | 7.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2926
Willdan Group
WLDN
$1.09B
| $1.03M | ﹤0.01% |
35,569
+1,680
| +5% | +$50.1K |
|
2927
Vroom Inc
VRM
$36.9M
| $1.02M | ﹤0.01% |
109,907
-32,582
| -23% | -$363K |
|
2928
Caribou Biosciences
CRBU
$143M
| $1.02M | ﹤0.01% |
621,205
-203,452
| -25% | -$650K |
|
2929
Aura Biosciences
AURA
$719M
| $1.02M | ﹤0.01% |
134,744
+28,500
| +27% | +$209K |
|
2930
Ericsson
ERIC
$32.2B
| $1.02M | ﹤0.01% |
164,745
+78,240
| +90% | +$437K |
|
2931
Century Therapeutics
IPSC
$368M
| $1.02M | ﹤0.01% |
398,380
+246,329
| +162% | +$779K |
|
2932
Criteo S.A. Ordinary Shares
CRTO
$1.07B
| $1.01M | ﹤0.01% |
+26,886
| New | +$984K |
|
2933
Vanguard Energy ETF
VDE
$9.97B
| $1.01M | ﹤0.01% |
7,922
-487
| -6% | -$63.4K |
|
2934
iRadimed
IRMD
$1.2B
| $1.01M | ﹤0.01% |
22,997
+3,224
| +16% | +$137K |
|
2935
Prudential
PUK
$37.8B
| $1M | ﹤0.01% |
54,652
+17,410
| +47% | +$328K |
|
|
ACRE
2936
Ares Commercial Real Estate
ACRE
$232M
| $999K | ﹤0.01% |
150,262
+11,084
| +8% | +$76.7K |
|
2937
Carter Bankshares
CARE
$756M
| $992K | ﹤0.01% |
65,633
+5,894
| +10% | +$73.7K |
|
2938
Jakks Pacific
JAKK
$297M
| $991K | ﹤0.01% |
55,345
+7,339
| +15% | +$145K |
|
2939
908 Devices
MASS
$317M
| $991K | ﹤0.01% |
192,462
-1,422
| -0.7% | -$8.59K |
|
2940
Amylyx Pharmaceuticals
AMLX
$2.16B
| $991K | ﹤0.01% |
521,619
+85,716
| +20% | +$166K |
|
2941
Latham Group
SWIM
$633M
| $987K | ﹤0.01% |
325,704
+10,711
| +3% | +$37.3K |
|
2942
NVE Corp
NVEC
$546M
| $986K | ﹤0.01% |
13,204
+449
| +4% | +$35.2K |
|
2943
Limoneira
LMNR
$236M
| $986K | ﹤0.01% |
47,386
+1,370
| +3% | +$27.6K |
|
2944
Ramaco Resources Class A
METC
$600M
| $986K | ﹤0.01% |
81,851
+13,410
| +20% | +$186K |
|
2945
Greenlight Captial
GLRE
$548M
| $980K | ﹤0.01% |
74,836
+6,062
| +9% | +$77.3K |
|
2946
Fox Class B
FOX
$21.8B
| $972K | ﹤0.01% |
30,365
+15,561
| +105% | +$470K |
|
2947
James Hardie Industries
JHX
$15.2B
| $964K | ﹤0.01% |
30,578
-703
| -2% | -$24.2K |
|
2948
Shore Bancshares
SHBI
$817M
| $964K | ﹤0.01% |
84,204
+6,560
| +8% | +$71.2K |
|
2949
Nokia
NOK
$50.7B
| $964K | ﹤0.01% |
254,899
+84,909
| +50% | +$314K |
|
2950
Taysha Gene Therapies
TSHA
$1.65B
| $963K | ﹤0.01% |
429,744
+378,282
| +735% | +$1.1M |
|
Similar funds
Charles Schwab's Q2 2024 Portfolio in Review
As of Q2 2024, Charles Schwab held 3,738 positions worth $525B, up 21% from $433B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Charles Schwab deployed $84.3B of net new capital in Q2 2024, opening 263 new positions and adding to 2,391 existing holdings. Its largest new stake was Schwab Fundamental US Small Company Index ETF: 195,294,508 shares worth $5.36B.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 23% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Texas Instruments, an estimated $367M trimmed.
- Charles Schwab's largest Q2 2024 buy was Schwab Fundamental US Small Company Index ETF: 195,294,508 shares worth $5.36B.
- Charles Schwab added most to Schwab Fundamental US Large Company Index ETF in Q2 2024, an estimated $8.54B increase.
- Charles Schwab's biggest Q2 2024 reduction was Texas Instruments, cutting an estimated $367M.
- Charles Schwab fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $335M.
- Charles Schwab's ten largest holdings make up 21% of its $525B portfolio in Q2 2024.
- Charles Schwab opened 263 new positions and closed 116 in Q2 2024.
- Charles Schwab's portfolio value rose 21% quarter-over-quarter to $525B.
Based on Charles Schwab's 13F filing for Q2 2024, filed 12 Aug 2024.